A Phase I/II, open label, dose-escalation clinical trial of TLC178 in paediatric rhabdomyosarcoma patients

Status: Planning

Phase of Trial: Phase I/II

Latest Information Update: 11 Jul 2018

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

09 Jul 2018 According to a Taiwan Liposome Company media release, Clearance received from the U.S. Food and Drug Administration (FDA) for the TLC178 Investigational New Drug (IND) applications, allowing Phase I/II trials to proceed in the US.
07 Jun 2018 New trial record
03 Jun 2018 According to a Taiwan Liposome Company media release, today announced the submission of an Investigational New Drug (IND) application with the U. S. Food and Drug Administration (FDA).

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com